New growth model
Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Kripa Mahalingam - July 26, 2019
What makes Intas the most valuable privately-held pharma company in India
Krishna Gopalan - June 09, 2017